These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 4918368)
1. Genetic factors in drug therapy. Evans DA Sci Basis Med Annu Rev; 1969; ():166-82. PubMed ID: 4918368 [No Abstract] [Full Text] [Related]
2. Pharmacogenetics. Evans DA Trans Med Soc Lond; 1970; 86():72-81. PubMed ID: 5531297 [No Abstract] [Full Text] [Related]
3. [Pharmacokinetics of drug preparations metabolized by N-acetyltransferase]. Skakun NP Klin Med (Mosk); 1982 Jan; 60(1):24-7. PubMed ID: 6122757 [No Abstract] [Full Text] [Related]
4. Advances in pharmacogenetics. Vesell ES Prog Med Genet; 1973; 9():291-367. PubMed ID: 4123249 [No Abstract] [Full Text] [Related]
5. [Determination of the phenotype of INH inactivation in pulmonary tuberculosis by means of an indirect method on the model of sulfamethazine]. Powłowska I; Rakowska Z Pneumonol Pol; 1978 Aug; 46(8):605-12. PubMed ID: 714703 [No Abstract] [Full Text] [Related]
6. Clinical consequences of polymorphic acetylation of basic drugs. Drayer DE; Reidenberg MM Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187 [TBL] [Abstract][Full Text] [Related]
7. Isoniazid and psuedocholinesterase polymorphisms. La Du BN Fed Proc; 1972; 31(4):1276-85. PubMed ID: 4556778 [No Abstract] [Full Text] [Related]
12. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications]. Eichelbaum M Internist (Berl); 1983 Mar; 24(3):117-27. PubMed ID: 6135670 [No Abstract] [Full Text] [Related]
13. [Clinical pharmacology of isoniazid (a review of the literature)]. Ivleva AIa Probl Tuberk; 1979 Jan; (1):18-26. PubMed ID: 368763 [No Abstract] [Full Text] [Related]
14. [Hepatotoxic effect of isoniazid (clinical, genetic and metabolic aspects)]. Chrostowski K; Kanabus P Pneumonol Pol; 1977; 45(1):49-54. PubMed ID: 834577 [No Abstract] [Full Text] [Related]
15. Pharmacogenetics. Du BN Med Clin North Am; 1969 Jul; 53(4):839-55. PubMed ID: 4892640 [No Abstract] [Full Text] [Related]
16. [Effect of hyaluronidase on the permeability of the blood-tissue barriers in the complex therapy of patients with pulmonary tuberculosis]. Khitrina GV; Zakutaeva VP; Tret'iakov AS Probl Tuberk; 1971; 49(9):51-5. PubMed ID: 5143430 [No Abstract] [Full Text] [Related]
17. [Clinically significant inherited differences in the mode of action of drugs]. Meyer UA; Meier PJ Schweiz Med Wochenschr; 1982 May; 112(19):666-9. PubMed ID: 7100864 [TBL] [Abstract][Full Text] [Related]
18. [Effectiveness and possibilities of application to ambulatory patients in our region of a pulmonary tuberculosis therapy by the intermittent administration (I.V.) of the triple association isoniazid-streptomycin-PAS (preliminary results after a year)]. Burghard G; Petitjean R; Schranz J; Scherrer B Rev Tuberc Pneumol (Paris); 1970; 34(3):439-53. PubMed ID: 5515514 [No Abstract] [Full Text] [Related]
19. [Genetic causes for the variability of effects and side effects of drugs]. Roots I Internist (Berl); 1982 Nov; 23(11):601-9. PubMed ID: 6759450 [No Abstract] [Full Text] [Related]
20. Inherited defects of hepatic drug metabolism. Küpfer A; Preisig R Semin Liver Dis; 1983 Nov; 3(4):341-54. PubMed ID: 6417793 [No Abstract] [Full Text] [Related] [Next] [New Search]